Intraocular properties of a repository urokinase receptor antagonist 36 peptide in rabbits

Current Eye Research

Volumn 35, Issue 8, 2010, Pages 742-750

  Falkenstein, Iryna A ^a   Cheng, Lingyun ^a   Jones, Terence R ^b   Freeman, William R ^a   Babson, Bruce ^c   Kozak, Igor ^a   Tammewar, Ajay M ^a   Barron, Erin C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Angstrom Pharmaceuticals   (United States)

^c MicroConstants   (United States)

Author keywords

Anti angiogenesis; Ocular drug delivery; Ocular toxicity; Rat CNV model; Urokinase receptor antagonist

Indexed keywords

A36 PEPTIDE; ENZYME INHIBITOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR ANTAGONIST; ANGIOGENESIS INHIBITOR; CYCLOPEPTIDE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOROID; CONTROLLED STUDY; DRUG FORMULATION; DRUG TISSUE LEVEL; ELECTRORETINOGRAM; EYE TOXICITY; HISTOPATHOLOGY; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA; TOXICITY TESTING; VITREOUS BODY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CHOROIDAL NEOVASCULARIZATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ELECTRORETINOGRAPHY; INJECTION; METABOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL AVAILABILITY; CHOROID; CHOROIDAL NEOVASCULARIZATION; DRUG DELIVERY SYSTEMS; ELECTRORETINOGRAPHY; INJECTIONS; INTRAOCULAR PRESSURE; PEPTIDES, CYCLIC; RABBITS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RETINA; VITREOUS BODY;

EID: 77955169153     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.486519     Document Type: Article

References (41)

1. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
2. Age-Related Eye Disease Study Research Group. Potential public health impact of age-related eye disease study results: AREDS report No. 11. Arch Ophthalmol. 2003;121:1621-1624.
3. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Opthtalmol. 2004;137:496-503.
4. Gass JD. Biomicroscopic and histopathologic consideration regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol. 1994;118:285-289.
5. Submacular Surgery Trials Research Group. Histopathology and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions. Report No. 7. Arch Ophthalmol. 2005;123:914-921.
6. Macular Photocoagulation Study Group. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol. 1996;114:400-412.
7. Sharma S, Bakal J, Oliver-Fernandez A, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: Results of an effectiveness study. Arch Ophthalmol. 2004;122:853-856.
8. Sadda SR, Pieramici DJ, Marsh MJ, et al. Submacular surgery trials pilot study investigators. Changes in lesion size after submacular surgery for subfoveal choroidal neovascularization in the submacular surgery trials pilot study. Retina. 2004;24:888-899.
9. American Academy of Ophthalmology. Macular translocation. Ophthalmology. 2000;107:1015-1018.
10. Armbrecht AM, Aspinal PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patents with wet age related macular degeneration. Br J Ophthalmol. 2004;88:1270-1273.
11. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-Tap report. Arch Ophthalmol. 1999;117:1329-1345.
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
13. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
14. Spaide RF, Laud K, Fine HF, et al. Intrravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina. 2006;26:383-390.
15. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
16. Freeman WR, Falkenstein I. Avastin and new treatments for AMD: Where are we? Retina. 2006;26:853-858.
17. Dano K, Andreasen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
18. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase type plasminogen activator system in cancer metastasis: A review. Int J Cancer. 1997;72:1-22.
19. Dear AE, Medcalf RL. The urokinase-type-plasminogen activator receptor (CD87) is a pleiotropic molecule. Eur J Biochem. 1998;252:185-193.
20. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: Recent advances and implications for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205-222.
21. Schmitt M, Wilhelm OG, Reuning U, et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis. 2000;14:114-132.
22. Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932-943.
23. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci. 1999;40:809-813.
24. Behzadian MA, Windsor LJ, Ghaly N, et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J. 2003;17:752-754.
25. McGuire PG, Jones TR, Talarico N, et al. The urokinase/urokinase receptor system in retinal neovascularization: Inhibition by A6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci. 2003;44:2736-2742.
26. Rakic JM, Lambert V, Munaut C, et al. Mice without uPA, tPA,or plasminogen genes are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:1732-1739.
27. Elner SG, Elner VM, Kindzelskii AL, et al. Human RPE cell lysis of extracellular matrix: Functional urokinase plasminogen activator receptor (uPAR), collagenase and elastase. Exp Eye Res. 2003;76: 585-595.
28. Das A, Boyd N, Jones TR, et al. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model. Arch Ophthalmol. 2004;122:1844-1849.
29. Koh HJ, Bessho K, Cheng L, et al. Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6. Invest Ophthalmol Vis Sci. 2004;45:635-640.
30. Koh HJ, Freeman WR, Azen SP, et al. Effect of a novel octapeptide urokinase fragment, A6, on experimental choroidal neovascularization in the monkey. Retina. 2006;26:202-209.
31. Colombo ES, Menicucci G, McGuire PG, et al. Hepatocyte growth factor/scatter factor promotes retinal angiogenesis through increased urokinase expression. Invest Ophthalmol Vis Sci. 2007;48:1793-1800.
32. Navaratna D, Menicucci G, Maestas J, et al. A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes. FASEB J. 2008;22:3310-3317.
33. Kobayashi H, Gotoh J, Fujie M, et al. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer. 1994;57:727-733.
34. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996;56:2428-2433.
35. Tressler RJ, Pitot PA, Stratton JR, et al. Urokinase receptor antagonists: Discovery and application to in vivo models of tumor growth. APMIS. 1999;107:168-173.
36. Le Gat L, Gogat K, Bouquet C, et al. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Ther. 2003;10:2098-2103.
37. Jones TR, Haney, DN, Varga J, et al. Cyclic peptide ligands that target urokinase plasminogen activator receptor. US Patent Application 20040204348, October 14, 2004. Retrieved August 8, 2009 from www.uspto.gov.
38. Koh HJ, Cheng L, Bessho K, et al. Intraocular properties of urokinase-derived antiangiogenic A6 peptide in rabbits. J Ocul Pharmacol Ther. 2004;20:439-449.
39. Cheng L, Hostetler KY, Lee J, et al. Characterization of a novel intraocular drug-delivery system using crystalline lipid antivial prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci. 2004;45:4138-4144.
40. Cheng L, Hostetler KY, Chaidhawangul S, et al. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho- ganciclovir. Invest Ophthalmol Vis Sci. 2002;43:515-521.
41. Lu S, Cheng L, Hostetler KY, et al. Intraocular properties of hexadecyloxypropyl-cyclic-cidofovir in Guinea pigs. J Ocul Pharmacol Ther. 2005;21:205-209.